These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35293306)

  • 21. The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.
    Angelis A; Harker M; Cairns J; Seo MK; Legood R; Miners A; Wiseman V; Chalkidou K; Grieve R; Briggs A
    Value Health; 2023 Oct; 26(10):1503-1509. PubMed ID: 37268059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An analysis of NICE's 'restricted' (or 'optimized') decisions.
    O'Neill P; Devlin NJ
    Pharmacoeconomics; 2010; 28(11):987-93. PubMed ID: 20936882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Public Reasoning and Health-Care Priority Setting: The Case of NICE.
    Rumbold B; Weale A; Rid A; Wilson J; Littlejohns P
    Kennedy Inst Ethics J; 2017; 27(1):107-134. PubMed ID: 28366905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.
    Lord J; Willis S; Eatock J; Tappenden P; Trapero-Bertran M; Miners A; Crossan C; Westby M; Anagnostou A; Taylor S; Mavranezouli I; Wonderling D; Alderson P; Ruiz F
    Health Technol Assess; 2013 Dec; 17(58):v-vi, 1-192. PubMed ID: 24325843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
    Cowles E; Marsden G; Cole A; Devlin N
    Appl Health Econ Health Policy; 2017 Aug; 15(4):469-477. PubMed ID: 28130691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
    Trouiller JB; Laramée P
    Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests.
    O'Mahony JF; Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):139-146. PubMed ID: 33462758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can the NICE "end-of-life premium" be given a coherent ethical justification?
    Cookson R
    J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Public funding of new cancer drugs: Is NICE getting nastier?
    Mason AR; Drummond MF
    Eur J Cancer; 2009 May; 45(7):1188-1192. PubMed ID: 19138512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias.
    Brown P; Calnan M
    Med Health Care Philos; 2013 May; 16(2):281-93. PubMed ID: 22198480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NICE's social value judgements about equity in health and health care.
    Shah KK; Cookson R; Culyer AJ; Littlejohns P
    Health Econ Policy Law; 2013 Apr; 8(2):145-65. PubMed ID: 22717361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
    Devlin N; Parkin D
    Health Econ; 2004 May; 13(5):437-52. PubMed ID: 15127424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. At the center of health care policy making: the use of health technology assessment at NICE.
    Stevens AJ; Longson C
    Med Decis Making; 2013 Apr; 33(3):320-4. PubMed ID: 23519880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
    Dietrich ES
    Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Guidelines: A NICE Way to Introduce Cost-Effectiveness Considerations?
    Drummond M
    Value Health; 2016; 19(5):525-30. PubMed ID: 27565268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
    O'Mahony JF; Paulden M
    Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.